Conditional sentence

Ten Companies Secure Spot in 2024 Class of the Comcast NBCUniversal SportsTech Accelerator

Retrieved on: 
Thursday, February 22, 2024

Today, 10 companies were accepted into the fourth class of the Comcast NBCUniversal SportsTech Accelerator , powered by Boomtown.

Key Points: 
  • Today, 10 companies were accepted into the fourth class of the Comcast NBCUniversal SportsTech Accelerator , powered by Boomtown.
  • The exciting opportunities and impactful outcomes of the SportsTech program have continued to fuel interest and demand with more than 1,500 applicants for this year’s class, from across 52 countries.
  • Since the first class in 2021, SportsTech alumni have achieved 132 pilots, partnerships, and commercial deals with consortium partners.
  • Comcast NBCUniversal SportsTech Class of 2024 includes:
    Aquimo drives value to brands, sports teams, and media through massive multiplayer mobile skill-sports games that integrate the motion of users’ phones and let millions play on any TV or live-stream broadcast – with no download required.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

GlobalData report highlights staggering $425.5 billion economic costs of obesity and overweight to U.S. Businesses and Employees in 2023

Retrieved on: 
Thursday, February 22, 2024

Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.

Key Points: 
  • Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.
  • Of the 158 million civilian employees on nonfarm payrolls, 30% (46.9M) are classified as having obesity and 34% (53.8M) have overweight.
  • Costs amounted to $347.5 billion attributed to obesity and $78 billion attributed to overweight.
  • Costs include $146.5 billion in higher medical costs for employees and their dependents, $82.3 billion in higher absenteeism (missed workdays), $160.3 billion in higher presenteeism (reduced productivity due to illness), $31.1 billion in higher disability costs, and $5.2 billion in higher Workers’ Compensation Program costs.

Best Vegan Meal Delivery (2024): Purple Carrot Plant-Based Meal Plans Reviewed by Compare Before Buying

Retrieved on: 
Wednesday, February 21, 2024

Compare Before Buying has spotlighted Purple Carrot as a leading option in its recent review for the best vegan meal delivery service of 2024.

Key Points: 
  • Compare Before Buying has spotlighted Purple Carrot as a leading option in its recent review for the best vegan meal delivery service of 2024.
  • Offering a comprehensive approach to vegan meal delivery, Purple Carrot presents two main meal options: Meal Kits and Prepared Meals.
  • Purple Carrot enhances the meal planning process with weekly deliveries tailored to subscribers’ preferences in meal frequency and serving size.
  • Compare Before Buying's review highlights Purple Carrot's status as a frontrunner in the vegan meal delivery service arena for 2024.

Global IL-17 Biologics Market Research Report 2023: Secukinumab, Ixekizumab, Bimekizumab, Brodalumab Market Insights and Forecasts, 2019-2022 and 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 21, 2024

The "Global IL-17 Biologics Market (2023 Edition): Analysis By Indication, By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By Country: Market Insights and Forecast (2024-2030)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global IL-17 Biologics Market (2023 Edition): Analysis By Indication, By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By Country: Market Insights and Forecast (2024-2030)" report has been added to ResearchAndMarkets.com's offering.
  • The Global IL-17 Biologics Market is expected to generate USD 10.9 Billion by the end of 2030, up from USD 4.37 Billion in 2022.
  • During the forecast period, 2024-2030, Global IL-17 Biologics is expected to expand at a CAGR of 12.3 %.
  • Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The Pharmaceutical Industry in South Africa 2023 - Profiles of 120+ Companies Including Aspen Pharmacare, Adcock Ingram, Bayer, GlaxoSmithKline, Pfizer, Clicks, Dis-Chem & Nativa - ResearchAndMarkets.com

Retrieved on: 
Monday, February 19, 2024

The "Pharmaceutical Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering.
  • More than 80% of South African pharmaceutical manufacturing and distribution revenue is from the private sector.
  • The pharmaceutical industry is well developed and supported by strong R&D and advanced manufacturing capabilities, including biotechnology manufacturing facilities.
  • There are profiles of 128 companies including local dominant players Aspen Pharmacare and Adcock Ingram, multinationals such as Bayer, GlaxoSmithKline and Pfizer and retailers Clicks and Dis-Chem and other players such as Nativa.

3D Printing High-Performance Plastics Market to Reach $520.0 Million by 2028: BCC Research

Retrieved on: 
Friday, March 8, 2024

BOSTON, March 8, 2024 /PRNewswire/ -- "According to the latest BCC Research study, the demand for Global 3D Printing High-Performance Plastics Market is estimated to increase from $163.6 million in 2022 to reach $520.0 million by 2028, at a compound annual growth rate (CAGR) of 21.4% from 2022 through 2028."

Key Points: 
  • BOSTON, March 8, 2024 /PRNewswire/ -- "According to the latest BCC Research study, the demand for Global 3D Printing High-Performance Plastics Market is estimated to increase from $163.6 million in 2022 to reach $520.0 million by 2028, at a compound annual growth rate (CAGR) of 21.4% from 2022 through 2028."
  • This comprehensive report focuses specifically on high-performance plastics within the expansive 3D printing industry, highlighting key materials such as polyamide, polyetherimide, polyetheretherketone, polyetherketoneketone, polyvinylidene difluoride, and polyphenylsulfone.
  • The forecasted revenue projections from 2022 to 2028 encompass each type, technology, end-user, and regional segment, offering a comprehensive outlook on the evolving landscape of the 3D printing high-performance plastics market.
  • The intersection of digitalization, robotics, and the growing demand for personalized, point-of-care medical solutions is fueling a surge in high-performance plastics (HPP) adoption in 3D printing.

Validation Institute Adds Keynote on GLP-1s, Lifestyle Strategies to Food as Medicine Strategy Summit, May 29-31, in Washington, D.C.

Retrieved on: 
Wednesday, March 6, 2024

NEEDHAM, Mass., March 6, 2024 /PRNewswire-PRWeb/ -- Validation Institute announced the addition of a keynote session, "Winning the Obesity Battle: Unlocking the Powerful Integration of Lifestyle Strategies and GLP-1s," at its Food as Medicine Strategy Summit, May 29-31, in Washington, D.C. (https://www.FoodMedSummit.com).

Key Points: 
  • Yet, employers have major questions when it comes to GLP-1 coverage, particularly regarding cost, trade-offs, and how they factor into recruiting and retaining top talent," said Haritha Krishnarathnam, EVP of Strategy and Content, at Validation Institute.
  • The Food as Medicine Strategy Summit is focused on measuring evidence-based food programs to prevent chronic disease, personalize treatment, and mitigate food security issues to produce better health outcomes.
  • The Summit is co-located with The Healthcare Innovation Congress, thINc360, which also takes place May 29-31, at The Westin Washington, DC Downtown.
  • Prospective attendees and sponsors are encouraged to visit http://www.FoodMedSummit.com for more information.

FibroBiologics Appoints Ruben A. Garcia as General Counsel

Retrieved on: 
Wednesday, March 6, 2024

"The addition of Ruben as our General Counsel represents a significant milestone for FibroBiologics in its journey as a publicly traded company," said Mr. O'Heeron.

Key Points: 
  • "The addition of Ruben as our General Counsel represents a significant milestone for FibroBiologics in its journey as a publicly traded company," said Mr. O'Heeron.
  • He most recently served as Senior Vice President, General Counsel and Corporate Secretary at AcelRx Pharmaceuticals, Inc. (n/k/a Talphera, Inc.).
  • Prior to his role at AcelRx, Mr. Garcia served as Senior Corporate Counsel and Assistant Secretary for Ultragenyx Pharmaceutical Inc. Mr. Garcia began his legal career at Vinson & Elkins L.L.P.
  • Forward-looking statements include information concerning FibroBiologics' advancement of its pipelines and the role to be played by, and impact of, the General Counsel.

Lindus Health Launches "All-In-One Metabolic CRO" Offering to Accelerate and Enhance Metabolic Clinical Trials

Retrieved on: 
Tuesday, March 5, 2024

This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

Key Points: 
  • This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
  • "Our All-in-One Metabolic CRO offering is designed to streamline study activities at every stage of research.
  • Lindus carries a site team with extensive resumes in the metabolic study execution that cover roles across PIs, CRCs, and more.
  • Lindus Health's all-encompassing Metabolic CRO offering empowers metabolic disease sponsors to run more timely and successful clinical trials while enhancing patient experience.